Life sciences news
-
Oxurion provides update on recruitment for KALAHARI Phase 2, Part B trial of novel PKal inhibitor THR-149 in diabetic macular edema and announces Board changes
Tuesday March 14th 2023
Read more
-
Mithra announces promising topline safety results from Donesta® Phase 3 Study in North America
Monday March 6th 2023
Read more
-
Mithra announces compelling initial preclinical data in its research collaboration on novel tyrosine kinase inhibitors with BCI Pharma
Thursday March 2nd 2023
Read more
-
Sequana Medical announces positive results from CHIHUAHUA, Phase 1 clinical trial of second-generation DSR product for congestive heart failure
Wednesday March 1st 2023
Read more
-
Galapagos announces topline results from Phase 3 DIVERSITY trial of filgotinib in Crohn’s disease
Thursday February 9th 2023
Read more
-
Sequana Medical announces the successful completion of pre-clinical studies with its second-generation DSR product for congestive heart failure
Wednesday February 8th 2023
Read more
-
Annals of the Rheumatic Diseases publishes results from two bimekizumab Phase 3 studies in axial spondyloarthritis
Wednesday January 18th 2023
Read more
-
Oxurion announces the continuation of KALAHARI Phase 2, Part B Study in diabetic macular edema following interim analysis
Friday December 16th 2022
Read more
-
Become a flanders.bio member
Your news here?
-
UCB announces positive Phase 3 studies for bimekizumab in hidradenitis suppurativa
Friday December 9th 2022
Read more
-
Oxurion: Interim analysis for KALAHARI trial planned by year-end 2022 with full top-line data expected in second half of 2023
Monday November 21st 2022
Read more
-
Rejuvenate Biomed’s newly appointed Clinical Advisory Board endorses Clinical Phase 2b strategy in sarcopenia
Tuesday November 15th 2022
Read more
More info?
Contact us
Ellen Telleir
Communication Coordinator
